Better Buy: AbbVie Inc. vs. Johnson & Johnson
They're partners. And they're rivals. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) co-market fast-growing cancer drug Imbruvica. However, the two big drugmakers compete against each other in the autoimmune disease market.
Johnson & Johnson has been a longtime favorite among investors. AbbVie has arguably been the best big pharma stock in recent years. But which is the better pick for investors now? Here's how AbbVie and J&J compare in the key categories of growth prospects, dividends, and valuation.
Image source: Getty Images.
Source: Fool.com
AbbVie Inc. Aktie
227,70 €
1,52 %
Klare Kaufstimmung: AbbVie Inc. hat 47 Buy-Einschätzungen und keine Sell-Einschätzung.
Ein Kursziel von 231 € für AbbVie Inc. signalisiert ein leicht positives Potenzial gegenüber dem aktuellen Kurs von 227.7 €.
